The European Commission has approved under the European Union Merger Regulation the proposed acquisition of the Austrian generic pharmaceuticals company EBEWE Spezial'Pharma Holding by Swiss drug major Novartis of Switzerland, a pharmaceutical company with both originator and generic activities, the latter through its Sandoz unit.
Novartis announced its intention to acquire the Austrian firm back in May, in a deal which values the latter at 925 million euros ($1.36 billion), in an all cash transaction.
The Commission concluded that the proposed transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.
Novartis is active in the development, production and distribution of both originator and generic pharmaceutical products and animal health products on a world-wide basis. EBEWE SP is active in the manufacture and distribution of specialty generic pharmaceutical products (with a focus on generic oncology products) and in the contract manufacturing of finished dose pharmaceuticals for other pharmaceutical companies.
The Commission says its examination found that the transaction would not raise competition concerns as significant market shares and overlaps between the parties' activities would only arise in a small number of markets where a sufficient number of credible competitors would remain after the proposed transaction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze